-
Je něco špatně v tomto záznamu ?
Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives
M. Mitrovic, G. Sistilli, O. Horakova, M. Rossmeisl
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, přehledy
Grantová podpora
17-11027S
Grantová Agentura České Republiky
722619
H2020 Marie Skłodowska-Curie Actions
PubMed
34291454
DOI
10.1111/eci.13650
Knihovny.cz E-zdroje
- MeSH
- fosfolipidy MeSH
- kyseliny mastné omega-3 terapeutické užití MeSH
- lidé MeSH
- nealkoholová steatóza jater farmakoterapie etiologie MeSH
- obezita komplikace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Prevalence of non-alcoholic fatty liver disease (NAFLD) increases in line with obesity and type 2 diabetes, and there is no approved drug therapy. Polyunsaturated fatty acids of n-3 series (omega-3) are known for their hypolipidaemic and anti-inflammatory effects. Existing clinical trials suggest varying effectiveness of triacylglycerol- or ethyl ester-bound omega-3 in the treatment of NAFLD, without affecting advanced stages such as non-alcoholic steatohepatitis. Preclinical studies suggest that the lipid class used to supplement omega-3 may determine the extent and nature of their effects on metabolism. Phospholipids of marine origin represent an alternative source of omega-3. The aim of this review is to summarise the available evidence on the use of omega-3 phospholipids, primarily in obesity-related NAFLD, and to outline perspectives of their use in the prevention/treatment of NAFLD. A PubMed literature search was conducted in May 2021. In total, 1088 articles were identified, but based on selection criteria, 38 original papers were included in the review. Selected articles describing the potential mechanisms of action of omega-3 phospholipids have also been included. Preclinical evidence clearly indicates that omega-3 phospholipids have strong antisteatotic effects in the liver, which are stronger compared to omega-3 administered as triacylglycerols. Multiple mechanisms are likely involved in the overall antisteatotic effects, involving not only the liver but also adipose tissue and the gut. Robust preclinical evidence for strong antisteatotic effects of omega-3 phospholipids in the liver should be confirmed in clinical trials. Further research is needed on the possible effects of omega-3 phospholipids on advanced NAFLD.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010851
- 003
- CZ-PrNML
- 005
- 20220506130516.0
- 007
- ta
- 008
- 220425s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/eci.13650 $2 doi
- 035 __
- $a (PubMed)34291454
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Mitrovic, Marko $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
- 245 10
- $a Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives / $c M. Mitrovic, G. Sistilli, O. Horakova, M. Rossmeisl
- 520 9_
- $a Prevalence of non-alcoholic fatty liver disease (NAFLD) increases in line with obesity and type 2 diabetes, and there is no approved drug therapy. Polyunsaturated fatty acids of n-3 series (omega-3) are known for their hypolipidaemic and anti-inflammatory effects. Existing clinical trials suggest varying effectiveness of triacylglycerol- or ethyl ester-bound omega-3 in the treatment of NAFLD, without affecting advanced stages such as non-alcoholic steatohepatitis. Preclinical studies suggest that the lipid class used to supplement omega-3 may determine the extent and nature of their effects on metabolism. Phospholipids of marine origin represent an alternative source of omega-3. The aim of this review is to summarise the available evidence on the use of omega-3 phospholipids, primarily in obesity-related NAFLD, and to outline perspectives of their use in the prevention/treatment of NAFLD. A PubMed literature search was conducted in May 2021. In total, 1088 articles were identified, but based on selection criteria, 38 original papers were included in the review. Selected articles describing the potential mechanisms of action of omega-3 phospholipids have also been included. Preclinical evidence clearly indicates that omega-3 phospholipids have strong antisteatotic effects in the liver, which are stronger compared to omega-3 administered as triacylglycerols. Multiple mechanisms are likely involved in the overall antisteatotic effects, involving not only the liver but also adipose tissue and the gut. Robust preclinical evidence for strong antisteatotic effects of omega-3 phospholipids in the liver should be confirmed in clinical trials. Further research is needed on the possible effects of omega-3 phospholipids on advanced NAFLD.
- 650 _2
- $a kyseliny mastné omega-3 $x terapeutické užití $7 D015525
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nealkoholová steatóza jater $x farmakoterapie $x etiologie $7 D065626
- 650 _2
- $a obezita $x komplikace $7 D009765
- 650 _2
- $a fosfolipidy $7 D010743
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Sistilli, Gabriella $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Horakova, Olga $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Rossmeisl, Martin $u Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000185344002 $7 xx0270807
- 773 0_
- $w MED00009632 $t European journal of clinical investigation $x 1365-2362 $g Roč. 52, č. 3 (2022), s. e13650
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34291454 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130508 $b ABA008
- 999 __
- $a ok $b bmc $g 1788792 $s 1162049
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 52 $c 3 $d e13650 $e 20210802 $i 1365-2362 $m European journal of clinical investigation $n Eur J Clin Invest $x MED00009632
- GRA __
- $a 17-11027S $p Grantová Agentura České Republiky
- GRA __
- $a 722619 $p H2020 Marie Skłodowska-Curie Actions
- LZP __
- $a Pubmed-20220425